NOTE: This video is ONLY available to watch in selected countries and geographies [geoip-content country=”AT, BE, BG, HR, CY, CZ, DK, EE, FR, FI, DE, GR, HU, IE, IT, LV, LT, LU, MT, NL, PL, PT, RO, SK, SI, CH, ES, SE, GB, IE, NO, CH”]
In this Renal Interventions roundtable, Andrew Holden (moderator; Auckland, New Zealand) is joined by Alexandros Mallios (Paris, France), Kate Steiner (Stevenage, UK) and Tobias Steinke (Düsseldorf, Germany) who discuss some of the key findings to come out of the 36-month IN.PACT AV Access trial data.
Holden outlines the key aims of the trial and highlights some of the most important data to come out of the study. “Durability of AV interventions is something that has not been well studied” notes Holden, adding that ”the IN.PACT AV Access trial, even at three years, is showing a highly significant patency advantage for the DCB arm compared to the standard PTA arm”.
The group discuss how the results might impact their management of these patients and how the reduction in interventions impacts on patient quality of life. They also look at how cost-effective the treatment is and address the safety concerns around paclitaxel before concluding by highlighting which patients are most suited for this treatment, how it has changed their practice and whether or not DCB treatment should be standard of care.
This video is sponsored by Medtronic.
[/geoip-content]
